{"schema_version":"secwatch.filing_event.v1","accession":"0001818331-25-000121","form_type":"8-K","ticker":"WGS","cik":"0001818331","company_name":"GeneDx Holdings Corp.","filed_at":"2025-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.108352+00:00","generated_at":"2026-05-17T06:16:46.275251+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"GeneDx appoints Thomas Fuchs, SVP & Chief AI Officer at Lilly, as Class I director","bullets":["Thomas Fuchs appointed to board effective September 17, 2025; board expands from 7 to 8 members.","Dr. Fuchs serves as SVP and Chief AI Officer at Eli Lilly, leading AI for drug discovery and clinical trials.","Initial RSU grant of $420,000 vesting over three years under non-employee director compensation policy.","Dr. Fuchs holds a doctorate in machine learning from ETH Zurich and founded Paige AI.","No transactions requiring disclosure under Item 404(a) and no arrangements with any person."],"urls":{"canonical":"https://secwatch.observer/filing/0001818331-25-000121","json":"https://secwatch.observer/filing/0001818331-25-000121.json","markdown":"https://secwatch.observer/filing/0001818331-25-000121.md","text":"https://secwatch.observer/filing/0001818331-25-000121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818331/000181833125000121/0001818331-25-000121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818331/000181833125000121/wgs-20250917.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:16:46.275251+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}